Business context and reporting period
Entity discrepancy: The request identifies Lipocine Inc., but the supplied filing is for Marathon Bar Corp. This summary reflects the supplied filing, not Lipocine.
Marathon Bar Corp. filed a Form 10-K for the fiscal year ended December 31, 2012. The filing describes a development-stage business seeking to source and sell organic energy bars, with no products or operating revenue to date. Its website remained under development; it had not identified suppliers or entered supplier arrangements.
Financial results and liquidity
- Revenue: $0 in 2012 and 2011, and cumulatively from inception on October 13, 2011.
- Net loss: $76,654 in 2012, versus $5,162 in 2011; cumulative loss was $81,816. 2012 loss per share was $0.02.
- Expenses: 2012 general and administrative expenses were $76,654, including $35,792 in professional fees and $33,975 in consulting fees.
- Cash flow: Cash used in operations was $62,866 in 2012. Financing provided $40,500, including proceeds from the sale of 500,000 shares; cash decreased by $22,366 to $577 at year-end.
- Balance sheet: Year-end assets were $577, all cash. Current liabilities were $11,893, including $11,655 of accounts payable and accrued expenses and $238 due to a shareholder. Stockholders’ deficit was $11,316. No material interest-bearing debt is reported; the shareholder advance is unsecured, non-interest-bearing, and due on demand.
- Margins and liquidity: Margins are not meaningful because there were no sales. The filing reports insufficient cash to meet planned business objectives and no committed financing sources.
Material changes versus the prior comparable period
Compared with 2011, the 2012 net loss increased to $76,654 from $5,162, while cash fell from $22,943 to $577. Accounts payable and accrued expenses rose to $11,655 from $7,367. The company issued 500,000 shares in 2012 for $50,000 gross proceeds, offset by $9,500 in offering costs; cash-flow statements report $40,500 of net financing proceeds. The filing says the company completed design of promotional materials in Q4 2012 and met potential manufacturers in Europe, but had not selected a manufacturer.
Outlook, risks and unusual items
- Management planned further legal and regulatory research and supplier selection in the first half of 2013, a detailed market plan in the third quarter, and website completion by the third quarter. These are operating plans, not quantified financial guidance.
- The independent auditor included a going-concern explanatory paragraph, citing no established revenue source, operating losses, and insufficient cash to meet the business plan. The statements contain no adjustments for the possible outcome of this uncertainty.
- Management expects further losses and says additional debt, equity, or a strategic arrangement may be needed. No financing agreements or arrangements were in place, and availability is uncertain.
- Key risks include failure to secure suppliers or financing, inability to execute the business plan or generate revenue, limited management experience and time, dependence on an unfinished website, and challenges protecting intellectual property. The company had no permanent employees other than its sole officer/director, who was unpaid and allocated up to 15 hours weekly.
- There was no established public trading market for the common stock. One officer/director owned 86% of shares outstanding as of February 26, 2013. Disclosure controls were deemed effective, but the filing did not include management’s assessment of internal control over financial reporting under a transition provision for newly public companies.
Important facts for investors to verify
- Confirm the issuer identity: the supplied 10-K is for Marathon Bar Corp., not Lipocine Inc.
- Review the auditor’s going-concern warning and the company’s very limited year-end cash against near-term obligations and planned spending.
- Verify whether the company subsequently secured financing, selected suppliers, obtained required certifications or approvals, and completed its website and sales launch.
- Reconcile the $50,000 gross share-sale proceeds with the $40,500 financing cash-flow amount and $9,500 of offering costs.
- Assess ownership concentration, the absence of an established trading market, and the ability to enforce judgments involving management located in Israel.